Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 24
- DOI:
- 10.3760/cma.j.issn.0366-6999.2011.24.003
- Key Word:
- hypo-fractionated;stereotactic body radiation therapy;lung;metastases;prognosis
Abstract： Background Metastatic lung cancer is one of the most common oncologic problems.This study aimed to evaluate the long-term clinical outcome of stereotactic body radiation therapy (SBRT) for metastatic lung tumors.Methods We retrospectively reviewed the 71 patients with lung metastases,who had 172 lesions treated with SBRT from January 2000 to December 2006.All patients were unfit or failed after surgery and/or chemotherapy.The median total dose was 48 Gy (range,30-60) in 4 (range,2-12) fractions.The median size of the irradiated lesions was 2.1 cm (range,0.9-7.9 cm).Results All but two patients received follow up.The median follow-up time was 24.7 months (range,2.9-114.4 months).The median follow-up time for living patients was 86.8 months (range,58.1-114.4 months).The 1-,3-,5-year local control and overall survival rates were 88.8％,75.4％,75.4％ and 78.9％,40.8％,25.2％.Multivariate analysis showed that the absence of extrapulmonary metastases (P=0.024; hazard ratio (HR),1.894; 95％ confidence interval (C/),1.086-3.303) and disease-free interval ≤12 months (P =0.014; HR,0.511; 95％ Cl,0.299-0.873) were independent prognostic factors.No grade 3 or more acute and late toxicities occurred.Only one patient developed a non-symptomatic rib fracture.Conclusion SBRT could be an alternative treatment to surgery for subsets of patients with lung metastases with favorable long-term survival and tolerable complications.
- [1]吴少雄,邓美玲,包勇,等.39例肺转移瘤立体定向放射治疗的疗效分析[J].2006,(7).
- [2]肖建平,徐国镇,张红志,等.肺转移瘤立体定向放疗初探[J].2006,(1).
- [3]S, Hellman,R R, Weichselbaum.Oligometastases.[J].1995,13.
- [4]Forquer JA,Fakiris AJ,Timmerman R.Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites.[J].2009,93(3).
- [5]Cardenes H,Kane M,Schefter TE,etc.Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.[J].2009,27(10).
- [6]J F, Fowler.The linear-quadratic formula and progress in fractionated radiotherapy.[J].1989,62.
- [7]Pennathur A,Landreneau RJ,Abbas G,etc.Radiofrequency and microwave ablation of lung tumors.[J].2009,100(8).
- [8]Ugo Pastorino,Marc Buyse,Godehard Friedel,etc.Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases[J].1997,113(1).
- [9]Wanders J,Kaplan RS,Eisenhauer EA,etc.New guidelines to evaluate the response to treatment in solid tumors (see comments)[J].2000,92(3).
- [10]Kubo A,Kamikubo Y,Kokubo M,etc.Extrapulmonary soft-tissue fibrosis resulting from hypofractionated stereotactic body radiotherapy for pulmonary nodular lesions.[J].2009,74(2).
- [11]Sakamoto M,Norihisa Y,Hiraoka M,etc.Stereotactic body radiotherapy for oligometastatic lung tumors.[J].2008,72(2).
- [12]Galvin,Paulus R,Timmerman R.Stereotactic body radiation therapy for inoperable early stage lung cancer.[J].2010,303(11).
- [13]Sheng K,Biedermann GB,Schefter TE,etc.Chest wall volume receiving>30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.[J].2010,76(3).
- [14]Chang EL,Wang JZ,Cardenes HR,etc.Stereotactic body radiation therapy: a novel treatment modality.[J].2010,7(1).
- [15]Mueller G,Krieger T,Gabor M,etc.Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation.[J].2009,74(1).